---
title: Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura
date: '2024-05-01'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38692292/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240502181147&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: During prophylaxis with recombinant ADAMTS13 in patients
  with congenital TTP, ADAMTS13 activity reached approximately 100% of normal levels,
  adverse events were generally mild or moderate in severity, and TTP events and manifestations
  were rare. (Funded by Takeda Development Center Americas and Baxalta Innovations;
  ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: During prophylaxis with recombinant ADAMTS13 in patients with congenital TTP, ADAMTS13 activity reached approximately 100% of normal levels, adverse events were generally mild or moderate in severity, and TTP events and manifestations were rare. (Funded by Takeda Development Center Americas and Baxalta Innovations; ClinicalTrials.gov number, ...